Credit Suisse Sees Up to a $7 Cut in Target Price to Clovis (CLVS) if Platinum Resistant/Refractory Removed; M&A Thesis Intact
- Wall St. set to open lower, weighed down by GE
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
- Microsoft (MSFT) Tops Q1 EPS by 8c
- Pre-Open Stock Movers 10/21: (ALKS) (RAI) (PFPT) (MSFT) Higher; (SGY) (TWLO) (RRGB) Lower (more...)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Credit Suisse analyst Kennen MacKay reiterated an Outperform rating and $41 price target on Clovis Oncology (NASDAQ: CLVS) after the company presented data from their NDA submission package in 3L+ BRCA+ ovarian cancer. The 0% ORR in platinum-refractory patients and 25% ORR in platinum-resistant patients were disappointing, though commentary focused on disease control rate in these patients, and the reviewer remained positive towards approval in patients with all platinum statuses.
MacKay said removing platinum-refractory from our model would lead to a (-$2) reduction in our TP of $41, while removing both platinum-resistant and –refractory would lead to a (-$7) TP reduction.
"We await a decision from the FDA, but continue to see potential for FDA approval with the applied-for-label in 3L+ g/sBRCA+ patients regardless of platinum status based on the disease control rate, which could lead to increases in survival," the analyst said.
The firm said their M&A thesis remains intact.
Shares of Clovis Oncology closed at $35.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades PayPal (PYPL) to Buy Following 'Solid' Q3 Results
- Yahoo! (YHOO): Downgrading To Hold, Raising PT - Jefferies
- PayPal (PYPL) PT Lifted to $48 at Mizuho Following Solid Q3
Create E-mail Alert Related CategoriesAnalyst Comments, Rumors
Related EntitiesCredit Suisse
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!